Table 2 Immunophenotype of composite lymphomas with NLPHL and DLBCL
Immuno-staining | DLBCL component positive | LP cells positive | Reduced expression in DLBCL component | Enhanced expression in DLBCL component | Identical expression in DLBCL and NLPHL component | Identical expression in DLBCL and NLPHL in simultaneous cases |
|---|---|---|---|---|---|---|
Bcl6 | 33/33 (100%) | 33/33 (100%) | 3% | 0% | 97% | 96% |
CD79a | 33/33 (100%) | 33/33 (100%) | 0% | 33% | 67% | 62% |
CD19 | 32/33 (97%) | 25/32 (78%) | 3% | 66% | 31% | 32% |
CD75 | 31/33 (94%) | 32/33 (97%) | 12% | 9% | 79% | 81% |
EMA | 24/33 (73%) | 27/33 (82%) | 18% | 6% | 76% | 85% |
J-chain | 24/33 (73%) | 27/33 (82%) | 27% | 3% | 70% | 77% |
Bcl2* | 20/32 (63%) | 27/33 (82%) | 0% | 38% | 63% | 69% |
MUM1 | 21/33 (63%) | 24/32 (72%) | 13% | 13% | 75% | 77% |
JAK2 | 12/30 (40%) | 4/27 (15%) | 0% | 23% | 77% | 82% |
CD10 | 12/33 (36%) | 2/33 (6%) | 0% | 33% | 67% | 69% |
p-STAT6 | 9/30 (30%) | 8/26 (31%) | 9% | 5% | 86% | 89% |
CD30 | 7/33 (21%) | 7/33 (21%) | 6% | 6% | 88% | 92% |
CD15 | 4/33 (12%) | 2/33 (6%) | 0% | 12% | 88% | 85% |
IgD | 4/33 (12%) | 5/33 (15%) | 3% | 0% | 97% | 96% |